Shots:
- insitro & BMS have extended their 5yr. collaboration (2020) to discover novel small molecule therapies for ALS using insitro’s AI-enabled ChemML platform
- The 1yr. extension will focus on developing therapies for a novel ALS target identified preclinically, with insitro receiving ~$20M in new funding & remaining eligible for discovery, development, regulatory, & commercial milestones exceeding $2B, plus royalties, under the 2020 deal
- ChemML integrates advanced in silico & lab capabilities, incl. large-scale data generation (QALs), ML-based modeling (with Eli Lilly), an AI-driven design loop, & robust compute power with 192 H100 GPUs for rapid small-molecule optimization
Ref: Bristol Myers Squibb | Image: Bristol Myers Squibb and insitro| Press Release
Related News:- Bristol Myers Squibb and Bain Capital Launch a New Company Focused on Immunology Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
